The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/
grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is
growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual
outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat
diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens
are underway to define better clinical care pathways.
Keywords: Anti-VEGF, diabetic macular edema, diabetes, neovascularization, rethinopathy, vision loss prevention.
Rights & PermissionsPrintExport